Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2468068 | 1.00 | HTT (0.52) | HTTPOLBNPC1CYP3A4LMNA | |
| SCHEMBL2150376 | 0.96 | HTT (0.53) | HTTPOLBNPC1CYP3A4LMNA | |
| SCHEMBL20631194 | 0.95 | HTT (0.51) | HTTPOLBNPC1CYP3A4LMNA | |
| SCHEMBL16067368 | 0.95 | HTT (0.51) | HTTPOLBNPC1CYP3A4LMNA | |
| SCHEMBL1742989 | 0.94 | POLB (0.47) | HTTPOLBNPC1CYP3A4LMNA | |
| SCHEMBL12221992 | 0.94 | HTT (0.47) | HTTPOLBNPC1CYP3A4LMNA | |
| SCHEMBL2618863 | 0.92 | HTT (0.53) | HTTPOLBNPC1CYP3A4LMNA | |
| SCHEMBL13785253 | 0.92 | HTT (0.53) | HTTPOLBNPC1CYP3A4LMNA | |
| SCHEMBL3325751 | 0.92 | LMNA (0.50) | HTTPOLBNPC1CYP3A4LMNA | |
| SCHEMBL4374707 | 0.92 | LMNA (0.50) | HTTPOLBNPC1CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177601-A1 | ANTI-HER2 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-09 | — | — | US | disclosed |
| US-20220168440-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DEPRIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-02 | — | — | US | disclosed |
| US-20220168438-A1 | COMBINATION OF ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND PARP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-02 | — | — | US | disclosed |
| CN-108093640-B | Site-specific antibody-drug conjugates | ADC治疗股份有限公司 | 2022-05-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168440-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DEPRIVATIVE CONJUGATE | CD79B, BTD, PDCD1 | HTT 2934/4885POLB 3101/4885NPC1 1852/4885 |
| US-20220168438-A1 | COMBINATION OF ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND PARP INHIBITOR | PARP2, PARP3, PARP1 | HTT 3479/4885POLB 87/4885NPC1 2494/4885 |
| US-20220177601-A1 | ANTI-HER2 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | ERBB2, BRD2, PA2G4 | HTT 2143/4885POLB 2382/4885NPC1 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.